Jump to content

RS130-180

Add links
From Wikipedia, the free encyclopedia

RS130-180
Clinical data
Other namesRS-130-180; N-(2-Propargyloxy)-2,5-dimethoxy-4-(dimethylamino)phenethylamine
Drug classβ-Arrestin-biased serotonin 5-HT2A receptor agonist
Identifiers
  • 2,5-dimethoxy-N,N-dimethyl-4-(2-((2-(prop-2-yn-1-yloxy)benzyl)amino)ethyl)aniline
PDB ligand
Chemical and physical data
FormulaC22H28N2O3
Molar mass368.477 g·mol−1
3D model (JSmol)
  • C(OC)1=C(N(C)C)C=C(OC)C(CCN([H])CC2=C(OCC#C)C=CC=C2)=C1
  • InChI=1S/C22H28N2O3/c1-6-13-27-20-10-8-7-9-18(20)16-23-12-11-17-14-22(26-5)19(24(2)3)15-21(17)25-4/h1,7-10,14-15,23H,11-13,16H2,2-5H3
  • Key:NDHJMNFRHQYXKX-UHFFFAOYSA-N

RS130-180, also known as N-(2-propargyloxy)-2,5-dimethoxy-4-(dimethylamino)phenethylamine, is a β-arrestin-biased serotonin 5-HT2A receptor agonist of the phenethylamine, 2C, and NBOMe families.[1][2][3] It is the NBOMe derivative in which the phenyl ring has an N,N-dimethylamino substitution at the 4 position and the 2-position methoxy group on the benzyl ring has been replaced with a propynyloxy group.[1]

The drug favors activation of β-arrestin signaling over Gq signaling.[1][2] RS130-180 is said to be useful for in-vitro studies, but to have suboptimal pharmacokinetic properties for in-vivo use.[1] The cryo-EM structures of the serotonin 5-HT2A receptor with RS130-180, as well as with various serotonergic psychedelics, have been solved and published by Bryan Roth and colleagues.[1][2]

RS130-180 was first described in the literature by 2022.[2][1] It was derived from an earlier compound called ZINC000341335936, which was identified via in-silico screening of 1.6 billion molecules for serotonin 5-HT2A receptor agonism with AlphaFold2.[4] RS130-180 was developed via structural modification of ZINC000341335936 by David E. Nichols and colleagues.[4]

See also

[edit]

References

[edit]
  1. ^ a b c d e f Gumpper RH, Jain MK, Kim K, Sun R, Sun N, Xu Z, et al. (March 2025). "The structural diversity of psychedelic drug actions revealed". Nature Communications. 16 (1): 2734. doi:10.1038/s41467-025-57956-7. PMC 11923220. PMID 40108183.
  2. ^ a b c d Gumpper RH, DiBerto J, Jain M, Kim K, Fay J, Roth BL (September 2022). Structures of Hallucinogenic and Non-Hallucinogenic Analogues of the 5-HT2A Receptor Reveals Molecular Insights into Signaling Bias (PDF). University of North Carolina at Chapel Hill Department of Pharmacology Research Retreat September 16th, 2022 – William and Ida Friday Center. [...] Here we present 8 new cryoEM structures covering all major compound classes for the 5HT2AR including a novel arrestin biased compound RS130-180. [...]
  3. ^ Ağacı E (22 March 2025). "Exploring Psychedelics: New Insights Into Therapeutic Mechanisms". The Pinnacle Gazette. Retrieved 22 March 2025. For instance, rs130-180, a non-hallucinogenic variant, was identified as a biased agonist with therapeutic implications.
  4. ^ a b Lyu J, Kapolka N, Gumpper R, Alon A, Wang L, Jain MK, et al. (June 2024). "AlphaFold2 structures guide prospective ligand discovery" (PDF). Science. 384 (6702): eadn6354. Bibcode:2024Sci...384n6354L. doi:10.1126/science.adn6354. PMC 11253030. PMID 38753765.
Retrieved from "https://en.wikipedia.org/w/index.php?title=RS130-180&oldid=1291067558"